Cochrane · systematic review · CD003137
Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma
Chauhan, BF, Ducharme, FM · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 3 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
LABA + ICS compared with LTRA + ICS for chronic asthma
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants with one or more exacerbations requiring systemic corticosteroids LABA + ICS vs LTRA + ICS | RR 0.87 [0.76, 0.99] | 8 studies · 6257 participants | High |
Morning PEFR: L/min change from baseline LABA + ICS vs LTRA + ICS | no estimate extracted | 11 studies · 6161 participants | Moderate |
FEV1: L change from baseline LABA + ICS vs LTRA + ICS | no estimate extracted | 10 studies · 4999 participants | High |
Rescue‐free days: % change from baseline LABA + ICS vs LTRA + ICS | no estimate extracted | 5 studies · 2612 participants | Moderate |
Rescue medication use: puffs/d change from baseline LABA + ICS vs LTRA + ICS | no estimate extracted | 7 studies · 4055 participants | High |
Withdrawals for any reason LABA + ICS vs LTRA + ICS | RR 0.84 [0.74, 0.96] | 13 studies · 6960 participants | Moderate |
Serious adverse events LABA + ICS vs LTRA + ICS | RR 1.33 [0.99, 1.79] | 9 studies · 6288 participants | Moderate |